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Background. The brain is deemed ‘‘immunologically privileged’’ due to sparse professional antigen-presenting cells and
lymphatic drainage, and to the blood-brain barrier. Although the actual extent of this privilege is controversial, there is general
consensus about the limited need in intracerebral neural grafts for immunosuppressive regimens comparable to those used in
other cases of allotransplantation. This has led over the past fifteen years to the use of either short-term or even no
immunosuppression in most clinical trials with foetal neural transplant in patients with Parkinson’s and Huntington’s disease.
Methodology/Principal Findings. We report biological demonstration of alloimmunisation without signs of rejection in four
grafted patients out of 13 studied during the course of a clinical trial involving fetal neural transplantation in patients with
Huntington’s Disease. Biological, radiological and clinical demonstration of an ongoing rejection process was observed in a fifth
transplanted patient. The rejection process was, however, fully reversible under immunosuppressive treatment and graft
activity recovered within six months. Conclusions/Significance. There had been, up to date, no report of documented cases
that could have cast a doubt on those procedures. Our results underline the need for a reconsideration of the extent of the so-
called immune privilege of the brain and of the follow-up protocols of patients with intracerebral grafts. It also suggests that
some of the results obtained in past studies with foetal neural transplants may have been biased by an unrecognized immune
response to donor cells.
Citation: Krystkowiak P, Gaura V, Labalette M, Rialland A, Remy P, et al (2007) Alloimmunisation to Donor Antigens and Immune Rejection Following
Foetal Neural Grafts to the Brain in Patients with Huntington’s Disease. PLoS ONE 2(1): e166. doi:10.1371/journal.pone.0000166
INTRODUCTION
Transplantation of cells and tissues to the mammalian brain and
CNS has been clinically assessed for more than 15 years, in several
hundred patients with Parkinson or Huntington Disease. Because
the brain was considered differently than almost all other organs, in
terms of the possibility of an immune response, little consideration
has beengiven upto now either to the potential existence ofadverse
consequences of a rejection process, or even to the existence any
sign of allo-immunisation in patients. The mechanisms underlying
this privilege are diverse, and probably cumulative, and results
from the blood– brain barrier, the absence of professional antigen-
presenting cells in the brain and the sparse lymphatic drainage
from the central nervous system (reviewed in [1]). Experimental
studies in animal models have, however, now revealed that the
previously held view that the brain was an absolute immunolog-
ically privileged site allowing indefinite survival without rejection of
grafts of cells was wrong. Activated lymphocytes can cross the BBB,
certain cells such as microglia may have an antigen presenting cell
capacity and there is lymphatic drainage from the brain into the
cervical lymph nodes. Thus, the brain should be regarded as a site
where immune responses can occur, albeit in a modified form. Up
to now, however, there had been no report of an immune rejection
process following foetal neural grafting to the brain of a patient. We
report here a first human case of characterized rejection, and
a number of transplanted patients with biological signs of all-
immunisation against the antigens of the foetal donors.
MATERIAL AND METHODS
A phase II study looking for therapeutic efficacy of foetal neural
grafts to the brain of patients with Huntington’s disease (‘‘MIG-
HD’’, ref. NCT00190450) is currently ongoing in Europe, follow-
ing the promising results of a pilot study [2,3,4]. The original
protocol has been approved by the CCPPRB of the Hospital
Henri-Mondor in Creteil on August 8, 2001. Additional protocols
and modifications to the letter of information and informed
consent related to the reported study were accepted by the same
committee on May 17, 2005 and January 16, 2006. Specific infor-
mation was given to patients, whose personal data are included in
this paper and all signed and informed consent for publication.
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with cyclosporin A stopped during the first year after bilateral
grafting, azathioprin and prednisolone progressively decreased
then stopped over the following months. The present study has been
organized as an ancillary to the main trial. It concerned 13 patients
(table 1), whohad received foetal neural transplants intwo successive
stereotaxic neurosurgical sessions –first aiming at the right striatum,
second at the left- three weeks to three months apart except in
patient 2, in which a surgical complication (subdural hematoma)
following the first graft precluded a second session.
Assessment protocols and imaging methods have been described
in referenced studies [3,4]. As a potential source for subsequent
controls, patient’s blood and foetal donor tissue were systemati-
cally taken and kept frozen, as part of the original protocol. Up to
now, it had never been necessary to study those samples, which
were defrozen for the present analysis in all 13 patients. Search for
anti-HLA I and II antibodies against foetal donor antigens were
not part of the original protocol (but are now an approved
addition). They were carried out on blood samples, and in one
case cerebrospinal fluid (patient 3), using classical techniques.
RESULTS
Fourteen months after grafting, one patient (patient 3) started to
exhibit general alteration of clinical status with weight loss of 22 kg
over three months, worsened choreic movements lateralised to the
left side, gait disorders and falls. Brain MRI showed an ongoing
encephalitic process with vasogenic oedema, extending from the
striatum to the frontal cortex mostly on the right side (Figure 1).
Positron emission tomography with 18F-deoxyglucose revealed
decreased metabolic activity in the same area of the right hemi-
sphere (Figure 1), whereas striatal metabolism increased by about
50% on the left side, as commonly observed in the presence of
functional grafts [3,4].
After ruling out an infection on the basis of the lack of alteration
of blood cells count, a graft rejection was hypothesized. A humoral
response was indeed documented with anti-HLA I –but not II–
antibodies in the blood (6 out of 30, i.e. cytotoxicity equivalent to
20% for a panel of 30 total lymphocyte suspensions) and in the
cerebrospinal fluid (2 out of 30, i.e. cytotoxicity equivalent to 7%
of the panel tested). The antibodies (IgG) were specifically directed
against A3 and A11 class I HLAs. Control assay in a serum sample
frozen immediately before surgery was negative for HLA
antibodies, indicating post-operative occurrence of the specific B
lymphocyte response. Biological demonstration of alloimmunisa-
tion against the graft tissues was provided by haplotyping
preserved frozen samples from the three foetuses used for grafting,
with HLA-A*3 allele in the foetus grafted on the right side, HLA-
A*11 in one of the two foetuses grafted in the left striatum.
Aggressive acute anti-inflammatory treatment associated to
reinstatement of the original immunosuppressive regimen rapidly
led to regression of MRI signs of encephalitis. General clinical
status remained altered for 4 more months then recovered, the
patient regaining more than half of her lost weight. Anti-HLA I
antibodies disappeared from blood and CSF samples. After
7 months of treatment, chorea lessened back to pre-rejection
levels, while gait disorders and falls disappeared. The patient
regained more than half of the lost weight. PET scan imaging then
revealed the presence in the right striatum of two areas of
increased metabolic activity (Figure 1) as compared not only to the
hypometabolic state observed during the rejection episode, but
also to preoperative values. After coregistration with the MRI,
both areas suggest the presence of neural grafts.
Alloimmunisation to donors’ antigens was sought in 12 other
MIG-HD grafted patients followed up different times beyond the
end of the period of immunosuppressive treatment. Four of them
demonstrated alloimmunisation to one of the donors although
none displayed either clinical or radiological signs of an ongoing
rejection process (patients 2, 4, 5 and 11; Table 1). No specific
pattern of alteration of blood cells counts could be identified in
successive assessments over time that would differentiate the five
alloimmunised patients (including the one with the ongoing
rejection process) and the seven non-immunised patients (see
Data S1). Because a search of alloimmunisation to foetal donor
antigens was not part of the MIG-HD protocol before the
identification of the rejection case reported here, it was not
possible to determine the time of occurrence of HLA antibodies in
the blood. It is interesting to mention, however, that one of the
four positive patients (patient 11) had been transplanted less than
six months before analysis as this shows that the humoral response
to allo-antigens may occur under full immunosuppressive
treatment, although it disappeared at a later time point, like in
patient 3.
Table 1. Clinical characteristics of the 13 grafted patients tested for the presence of antibodies against foetal donors’ HLA I
antigens.
..................................................................................................................................................
P a t i e n t 1 2 3 4 5678 9 1 0 1 1 1 21 3
Disease duration (y) 11 8 5 6 9977 7 5 4 4 6
TFC 10 10 11 1 1971 0 1 38 9 1 0 1 21 3
UHDRS 55 61 28 36 37 64 32 23 64 26 50 28 15
MDRS 111 120 125 124 122 133 122 143 127 122 135 132 139
AC HLA I 2 ++ ++ 222 2 2 + 22
Cyclosporin A (m) 9 13 9 9 6777 ongoing ongoing 6 6 ongoing
Imurel/solupred (m) 13 12 10 12 12 17 12 8 ongoing ongoing ongoing 12 ongoing
Adverse effects 2 sdh Rejection 2 2222 2 inf 2 sdh 2
Results of evaluation scales for general capacity (TFC, total functional capacitance), motor symptoms (UHDRS, motor part of the Unified Huntington Disease Rating
Scale) and cognitive functions (MDRS, Mattis Dementia Rating Scale) are indicated at the time of grafting. The situation of the immunosuppressive treatment is
indicated at the time of analysis of antibodies, either in months (m) when they have been interrupted according to the protocol (see text), or else as ‘‘ongoing’’. Serious
adverse effects besides rejection (patient 3, in bold) were subdural hematomas (sdh, in two cases) and cerebral infection (inf, 1 case). For sake of anonymity, individual
patients’ age, sex and number of CAG repeats are not shown. They were all between 39 and 55 years of age at the time of grafting; there were 5 women and 8 men;
CAG repeats ranged between 42 and 49.
doi:10.1371/journal.pone.0000166.t001
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Immune Rejection in the Brain
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The main result of our study is the demonstration that a large
proportion of patients who received intracerebral foetal neural
grafts exhibited biological signs of allo-immunisation to donors’
antigens, in general a few months after interruption of the
immunosuppressive treatment. In one patient, this was accompa-
nied by overt clinical, radiological and biological signs of an
ongoing immune rejection process; this process was, however, fully
reversible under treatment. These results call for a reconsideration
of results of previous foetal neural grafts trials in which a
deleterious effect of potentially similar immune responses was not
examined. They underline the need for careful follow up of
patients and appropriate immunosuppressive treatment in future
clinical trials.
Our results show that foetal neural cells grafted to the brain may
provoke a humoral response as other organ transplants [5], with
specific alloimmunisation to donors’ antigens in a significant
proportion of patients. The role of the humoral response has been
extensively studied in the pathogenesis of acute or hyperacute
vascular rejection, but is now also demonstrated in chronic
rejection. The appearance of HLA antibodies after transplantation
is associated, in kidney, pancreas, heart and lung transplantation
with poor transplant outcome and the occurrence of both acute
and chronic rejection (review in [6]). After kidney transplantation,
the humoral response was generally detected before transplant
failure [7], suggesting that HLA antibodies could be responsible
for transplant dysfunction. Previous studies have found wide
variations in the percentage of patients with HLA antibodies after
kidney transplantation, ranging between 12 and 60%. Our results
are, thus, well in keeping with those obtained in other organ
transplants, indicating that the immunological privilege of the
brain may not extend as much to the activation of a humoral
response. There are, however, major differences between the
consequences of that allo-immunisation in the brain as compared
to other organs. It is worth noting, first, that the presence of anti-
HLA antibodies was not accompanied in all except one of our
cases by overt signs of graft rejection. Second, even in the one case
in whom an ongoing rejection process was identified, full reversion
of the deleterious process could be obtained under treatment,
including a functional recovery of the graft. This, together with
previous evidence in animals [8,9], showing in particular that
triggering of an immune response may not lead to complete tissue
Figure 1. Brain imaging of the rejection process in patient 3 and its reversion under treatment. Magnetic resonance imaging and metabolic
activity using
18F-deoxyglucose before surgery (T0), during the rejection process (T1) and after 6 months of reinstated immunosuppressive treatment
(T2) are shown separately (upper and middle panel, respectively), then co-registered (lower panel). The white arrow indicates the right striatum. The
false colour scale shows levels of metabolic activities from lowest (min) to highest (max).
doi:10.1371/journal.pone.0000166.g001
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existence of specific features of an immune response in the brain.
Our results call for reconsideration of the results of past clinical
trials with foetal neural grafts performed, for most of them, in
patients with Parkinson’s disease. To our knowledge, there has
been no systematic follow up of possible immune responses to
grafts up to now in those trials, and immunosuppressive regimens
have been extremely diverse, ranging from a classical long term
tri-therapy [10,11] down to no treatment altogether [12], with
various intermediate situations comparable to the one used in this
study [13,14]. What could have been the consequences of an
inappropriate, or insufficiently maintained immunosuppressive
regimen is but, at this point, a matter of speculation. Nevertheless,
it is worth underlining the fact that at least in one large scale study
a negative evolution of the results over time, following a first
period of clinical improvement, was hypothetically related to the
event of an otherwise undetermined immune response [14]. Also
possibly relevant to our data is the appearance of major dyskinetic
adverse effects in the long term following grafting in patients with
Parkinson’s disease [12]. Alloimmunisation to donors may indeed
have contributed to those partially negative results and to the
occurrence of delayed side-effects as, even in the absence of overt
signs of a rejection process, effected neural grafts produce and
elicit cytokine responses that may contribute to adverse functional
effects observed in patients.
Our results clearly point to the fact that immune responses in
the brain are complex, but cannot be ignored when it comes to
repair strategies involving cellular transplants. New experimental
studies are definitely needed in order to better comprehend and
delineate the immunological privilege of the brain. The results of
those experimental studies will allow us, in the future, to define
more precisely the extent to which immunosuppressive regimens
can be adapted to the specific case of intracerebral transplants.
Until this redefinition is available, long term immunosuppressive
treatment and thorough follow up of the immunological status of
patients are likely indispensable.
SUPPORTING INFORMATION
Data S1 Blood cell counts. First grafting session is set at Time 0.
Other times are indicated in months in relation to it. Counts
corresponding to periods of presence of anti-foetal HLA antibodies
identified in the blood of the patients are in bold.
Found at: doi:10.1371/journal.pone.0000166.s001 (0.27 MB
DOC)
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